Clinical trials: Recurrent Lung Carcinoma
Non-small Cell Lung Cancer
Allogeneic PB103 (NK Cells) Therapy in Non-small Cell Lung Cancer (NSCLC) Patients
Objectives: To determine the safety, tolerability, and efficacy of allogeneic PB103 in patients with IIIb/IV or refractory non-small-cell lung cancer
- Trial name
- NCT04616209
- Testing
- donor-derived NK cell infusion
- Where
- Taiwan
- Volunteers
- 24 people
- Sponsor
- Precision Biotech Taiwan Corp.
Recurrent Extensive Stage Small Cell Lung Carcinoma
HTMC0435 and Temozolomide in Treating Patients With Small Cell Lung Cancer
The Phase 1b part of this clinical trial is to investigate the safety and pharmacokinetic (PK) characteristics of HTMC0435 tablets combined with temozolomide in patients with various advanced solid tumors (recurrent small cell…
- Trial name
- NCT05728619
- Testing
- HTMC0435, Temozolomide
- Where
- 3 sites in China
- Volunteers
- 64 people
- Sponsor
- Shanghai Yidian Pharmaceutical Technology Development Co., Ltd.
Carcinoma, Non-Small-Cell Lung
Three Combinations Of Docetaxel And Irinotecan For Recurrent Or Metastatic Non Small Cell Lung Cancer
A multicenter randomized phase II study evaluating the activity and tolerability of three different combinations of docetaxel (taxotere) and irinotecan (campto) as second line therapy for recurrent or metastatic non small cell…
- Trial name
- NCT00139711
- Testing
- Irinotecan, Docetaxel
- Where
- 15 sites in Italy
- Volunteers
- 138 people
- Sponsor
- Pfizer
HER2-positive Advanced Solid Tumor
A Phase 1/2a Study of DB-1303/BNT323 in Advanced/Metastatic Solid Tumors
This is a dose-escalation and dose-expansion Phase 1/2a trial to evaluate the safety and tolerability of DB-1303/BNT323 in subjects with advanced solid tumors that express HER2.
- Trial name
- NCT05150691
- Testing
- DB-1303/BNT323, Pertuzumab Injection, Ritonavir
- Where
- 102 sites in United States, Australia and 4 more
- Volunteers
- 796 people
- Sponsor
- DualityBio Inc.
Non-Small Cell Lung Cancer
A Study of Atezolizumab Compared With a Single-Agent Chemotherapy in Treatment Naïve Participants With Locally Advanced or Recurrent or Metastatic Non-Small Cell Lung Cancer Who Are Deemed Unsuitable For Platinum-Doublet Chemotherapy
This Phase III, global, multicenter, open-label, randomized, controlled study will evaluate the efficacy and safety of atezolizumab (an anti-programmed death-ligand 1 [anti-PD-L1] antibody) compared with a single agent…
- Trial name
- IPSOS (NCT03191786)
- Testing
- Atezolizumab (MPDL3280A), an engineered anti-PD-L1 antibody, Vinorelbine, Gemcitabine
- Where
- 91 sites in Argentina, Belgium and 22 more
- Volunteers
- 453 people
- Sponsor
- Hoffmann-La Roche
NSCLC Adenocarcinoma, Gastroesophageal Cancer (GC)
A Study of IDE892 as Monotherapy and Combination in MTAP-deleted Advanced Solid Tumors
This is a multicenter clinical study to evaluate the safety, efficacy, and Pharmacokinetics (PK) of IDE892 as monotherapy and in combination with other agents including IDE397 in participants with methylthioadenosine…
- Conditions
- NSCLC Adenocarcinoma, Gastroesophageal Cancer (GC), Gastric Adenocarcinoma, Adenocarcinoma of Esophagus
- Trial name
- NCT07277413
- Testing
- IDE892, IDE397
- Where
- 23 sites in United States
- Volunteers
- 260 people
- Sponsor
- IDEAYA Biosciences
Ovarian Cancer, Colorectal Cancer
EMD 273066 in Patients With Recurrent EpCAM Positive Ovarian, Prostate, Colorectal or Non-small Cell Lung Cancers When First Given Cyclophosphamide
This study is looking at the safety and tolerability of the experimental biological drug EMD 273066 when given with low dose cyclophosphamide to patients with recurring EpCAM positive ovarian, prostate, colorectal or non-small…
- Conditions
- Ovarian Cancer, Colorectal Cancer, Carcinoma, Non-small-cell Lung, Prostate Cancer
- Trial name
- NCT00132522
- Testing
- EMD 273066
- Where
- 5 sites in United States, Switzerland
- Volunteers
- 45 people
- Sponsor
- EMD Serono
Non Small Cell Lung Cancer, Metastatic NSCLC
Study of GT103 in Combination With Pembrolizumab in Refractory, Metastatic Non-Small Cell Lung Cancer
This open-label, non-randomized Phase II trial is designed to assess the safety and tolerability of GT103 in combination with pembrolizumab in adult subjects with relapsed or refractory, metastatic NSCLC.
- Conditions
- Non Small Cell Lung Cancer, Metastatic NSCLC, Recurrent Non Small Cell Lung Cancer
- Trial name
- NCT05617313
- Testing
- Pembrolizumab, GT103
- Where
- 6 sites in United States
- Volunteers
- 21 people
- Sponsor
- Ryan Dackor
Ovarian Cancer, Fallopian Tube Cancer
Study of COTI-2 as Monotherapy or Combination Therapy for the Treatment of Malignancies
Activity of COTI-2 has been demonstrated in various cancer tumor models. With its p53- and AKT-based mechanisms of action, COTI-2 is anticipated to be highly relevant in treatment of patients with gynecologic malignancies or head…
- Conditions
- Ovarian Cancer, Fallopian Tube Cancer, Endometrial Cancer, Cervical Cancer
- Trial name
- COTI2-101 (NCT02433626)
- Testing
- COTI2, Cisplatin
- Where
- United States
- Volunteers
- 51 people
- Sponsor
- Critical Outcome Technologies Inc.
Lung Cancer
Lometrexol Plus Folic Acid in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer
RATIONALE: Lometrexol may stop or slow the growth of tumor cells by blocking the enzymes necessary for tumor cell growth. Folic acid may be effective in preventing or lessening the side effects of lometrexol.
- Trial name
- NCT00033722
- Testing
- folic acid, lometrexol
- Where
- 7 sites in United States
- Sponsor
- Tularik
Non-Small Cell Lung Cancer
A Study to Evaluate the Single-Agent Lenalidomide in Subjects With Recurrent Non-Small-Cell Lung Cancer
Subjects who qualify will receive single agent lenalidomide once daily on days 1-21 of 28 day cycles. Subjects will continue until disease progression is documented.
- Trial name
- NCT00179686
- Testing
- CC-5013
- Where
- 6 sites in United States
- Volunteers
- 40 people
- Sponsor
- Celgene Corporation
Lung Cancer, Non-Small Cell Lung Cancer
An Immuno-Therapy Study of Experimental Medication BMS-986205 Given With Nivolumab With or Without Chemotherapy Compared to Chemotherapy in Participants With Previously Untreated Stage IV or Recurrent Non-Small Cell Lung Cancer
This is a study of experimental medication BMS-986205 given with Nivolumab with or without chemotherapy compared to chemotherapy in participants with previously untreated stage IV or recurrent non-small cell lung cancer.
- Trial name
- NCT03417037
- Testing
- BMS-986205, Nivolumab, Chemotherapy
- Where
- 83 sites in United States, Australia and 15 more
- Sponsor
- Bristol-Myers Squibb
Solid Tumors, Ovarian Cancer
A Study of DC05F01 in Chinese Patients With Recurrent/Refractory Ovarian Cancer and Other Advanced Solid Tumors
This study is a multicenter, open-label, cohort expansion Phase Ib/IIa trial designed to evaluate the efficacy, safety, and pharmacokinetic (PK) profile of DC05F01 in patients with recurrent/refractory ovarian cancer and other…
- Conditions
- Solid Tumors, Ovarian Cancer, Small Cell Lung Cancer
- Trial name
- NCT06873555
- Testing
- DC05F01
- Where
- 2 sites in China
- Volunteers
- 60 people
- Sponsor
- Heronova Pharmaceuticals
Lung Cancer
Polyglutamate Paclitaxel Compared With Gemcitabine or Vinorelbine in Treating Patients With Advanced or Recurrent Non-Small Cell Lung Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells.
- Trial name
- NCT00054197
- Testing
- gemcitabine hydrochloride, paclitaxel poliglumex, vinorelbine tartrate
- Where
- 10 sites in United States
- Sponsor
- CTI BioPharma
Stomatitis
An Open-label, Single-arm Study of Prophylaxis for Datopotamab Deruxtecan (Dato-DXd) -Related Stomatitis in Eligible Patients With Metastatic or Inoperable Locally Recurrent Breast Cancer or Locally Advanced or Metastatic Epidermal Growth Factor Receptor-Mutated Non-small Cell Lung Cancer.
This is a multicenter, open-label, single-arm study of prophylaxis for Dato-DXd-related stomatitis in eligible patients with metastatic or inoperable locally recurrent breast cancer or locally advanced or metastatic Epidermal…
- Trial name
- TROPION-SWISH (NCT07357597)
- Testing
- Dexamethasone mouthwash, Datopotamab Deruxtecan (Dato-DXd)
- Where
- 41 sites in United States
- Volunteers
- 100 people
- Sponsor
- AstraZeneca
Carcinoma, Non-Small-Cell Lung
An Exploratory Clinical Study of TILs in the Treatment of Recurrent / Refractory Non-small Cell Lung Cancer (NSCLC)
This study is an open, single-arm, dose-escalating phase I exploratory clinical trial to observe the safety, tolerability and preliminary efficacy of different doses of TILs in the treatment of relapsed and refractory…
- Trial name
- NCT04919616
- Testing
- TILs（Tumor Infiltrating Lymphocytes）
- Volunteers
- 15 people
- Sponsor
- Shanghai OriginCell Therapeutics Co., Ltd.
Advanced Solid Tumors, EGFR Positive Non-small Cell Lung Cancer
First-in-human Study of Oral TP-0903 (a Novel Inhibitor of AXL Kinase) in Patients With Advanced Solid Tumors
TP-0903 is a novel oral inhibitor that targets AXL kinase and reverses the mesenchymal phenotype associated with advanced cancers.
- Conditions
- Advanced Solid Tumors, EGFR Positive Non-small Cell Lung Cancer, Colorectal Carcinoma, Recurrent Ovarian Carcinoma
- Trial name
- NCT02729298
- Testing
- TP-0903
- Where
- 16 sites in United States
- Volunteers
- 177 people
- Sponsor
- Sumitomo Pharma America, Inc.
Neoplasms
A Study of the Safety and Effects of ADH-1 Given Intravenously as a Single Agent
N-cadherin, a protein involved in blood vessel cell binding, is increased as cancer progresses, and is on the surface of many tumor cells. ADH-1 blocks N-cadherin.
- Trial name
- NCT00264433
- Testing
- ADH -1 (Exherin™)
- Where
- 11 sites in United States, Canada
- Sponsor
- Adherex Technologies, Inc.
Carcinoma, Non-Small-Cell Lung
Observational Study to Evalute the Efficacy and Safety of Avastin (Bevacizumab) in Addition to Platinum-Based Chemotherapy for First-Line Treatment of Participants With Non-Small Cell Lung Cancer
The purpose of this study is to examine the efficacy of Bevacizumab in addition to platinum-based chemotherapy for first-line treatment of participants with advanced stage (IIIB/IV) non-small cell lung cancer (NSCLC) other than…
- Trial name
- AVALANCHE (NCT03170284)
- Testing
- Bevacizumab
- Where
- 33 sites in Hungary
- Volunteers
- 150 people
- Sponsor
- Hoffmann-La Roche
Non-small Cell Lung Cancer
BPI-7711 Capsule in Patients With EGFR Mutation T790M Positive Non-small Cell Lung Cancer
Lung cancer has the highest incidence rate in China and is also a very common cancer in the world. BPI-7711 is a new drug developed for patients with non-small cell lung cancer.
- Trial name
- NCT03386955
- Testing
- BPI-7711 Capsule
- Where
- 4 sites in China
- Volunteers
- 215 people
- Sponsor
- Beta Pharma Shanghai